From January 26 to 27, the 19th Asian Financial Forum was held in Hong Kong.

On January 26, the 0.5 mg/patch pediatric low-dose formulation of the Tulobuterol Patches (Deruituo®), the first domestic generic developed by Beijing Tide Pharmaceutical, a subsidiary of Sino Biopharm (1177.HK), officially received a drug registration certificate from the National Medical Products Administration (NMPA).

Recently, Chia Tai Tianqing, a core enterprise of Sino Biopharm (1177.HK), announced that its oral Class 1 innovative drug for chronic hepatitis B virus (HBV) infection, the core protein allosteric modulator TQA3605, has met the primary study endpoint in its Phase II clinical study.

During the World Economic Forum Annual Meeting 2026 (the "Winter Davos Forum"), Sino Biopharm's (1177.HK) active M&A transactions and globalized innovation strategy attracted attention from numerous media outlets at home and abroad.

The prevalence of allergic rhinitis in China has risen from 11.1% to 17.6%, with approximately 200 million patients suffering from the disease.

On January 15, local time, Sino Biopharm (1177.HK) attended the 44th J.P. Morgan Healthcare Conference and gave a systematic presentation on the company's strategic M&A, technology platforms, and innovative pipeline, showcasing its steady pace of accelerating innovation and expansion to the global market.

On January 14, following the completion of the major transaction of a RMB 1.2 billion full acquisition of Hygieia, Ms. Theresa Tse, Chairwoman of the Board of Sino Biopharmaceutical Limited (1177.HK), was interviewed by the globally renowned financial media outlet Bloomberg. She elaborated on the strategic significance of this acquisition and answered questions regarding future investment layout, implementation of the globalization strategy, and other topics.

On January 13, Sino Biopharm (1177.HK) announced that it will fully acquire Hangzhou Hygieia Pharmaceuticals Co., Ltd. (hereinafter referred to as "Hygieia"), a domestic innovative drug company in the small interfering RNA (siRNA) field, for a total price of RMB 1.2 billion.